Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/15/26
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease MarketSeeking Alpha • 01/03/26
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhDGlobeNewsWire • 12/02/25
Zevra Therapeutics (ZVRA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/05/25
Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation ConferenceGlobeNewsWire • 10/29/25
Zevra Therapeutics (ZVRA) Surges 12.3%: Is This an Indication of Further Gains?Zacks Investment Research • 10/16/25
Zevra Therapeutics (ZVRA) Soars 10.4%: Is Further Upside Left in the Stock?Zacks Investment Research • 09/25/25
Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)GlobeNewsWire • 09/18/25
Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)GlobeNewsWire • 09/04/25
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)GlobeNewsWire • 08/28/25
Zevra Therapeutics to Participate at Upcoming Investor Conferences in SeptemberGlobeNewsWire • 08/26/25
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates (Revised)Zacks Investment Research • 08/15/25
Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.Investors Business Daily • 08/13/25
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/12/25
What Makes Zevra Therapeutics (ZVRA) a Good Fit for 'Trend Investing'Zacks Investment Research • 08/08/25
Zevra Therapeutics (ZVRA) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • 08/05/25
Does Zevra Therapeutics (ZVRA) Have the Potential to Rally 117.11% as Wall Street Analysts Expect?Zacks Investment Research • 07/31/25